New Colorectal Cancer Screening Research Trial Approved and Set to Begin

    REGINA, June 11 /CNW/ - A simple blood test may be all that is needed to
detect colorectal cancer risk. The launch of a new colorectal cancer screening
research trial supported by the Saskatchewan Ministry of Health is scheduled
to begin in the next two weeks.
    "Our government is ready for growth. We're open to new opportunities and
new ways of providing health services," Health Minister Don McMorris said.
"This initiative is another indication that Saskatchewan companies can not
only compete - they can lead the way for others around the country and around
the world."
    The Saskatchewan Cancer Agency and Phenomenome Discoveries have
collaborated to develop a clinical trial protocol to evaluate Phenomenome's
new serum test for colorectal cancer risk screening, discovered and validated
at Phenomenome's lab in Saskatoon. The clinical trial has received the
necessary approvals and 5,000 patients will be recruited for the two year
Regina-centered trial.
    All patients undergoing a colonoscopy procedure will be asked to
volunteer some medical history and two blood samples which will be analyzed at
the Saskatchewan Disease Control Laboratory using Phenomenome's new risk
screening test. Results of the blood test and colonoscopy will be compared and
the Cancer Agency will assess the utility of the blood test as a
pre-colonoscopy screening tool. Results will be available in late 2009.
    Dr. James McHattie, head of gastroenterology for the Regina Qu'Appelle
Health Region and the lead clinical investigator on the trial, says, "This
blood test gives great promise to be able to identify with great accuracy a
segment of the population at high risk for development of colon cancer at a
stage where intervention would either prevent or cure the cancer."
    Phenomenome's test, the first of its kind, detects a metabolite called
"gTA", which extensive international validation studies have shown is
deficient in the blood of up to 90% of people with colorectal cancer.
Dr. Dayan Goodenowe, President and CEO of Phenomenome Discoveries, says, "It
is through collaboration with the trial's sponsoring agencies that we've been
able to undertake the most extensive evaluation of colon pathology and
metabolic risk factors in history."
    If the trial is successful, this simple blood test will assist
Saskatchewan doctors in identifying those people at elevated risk for colon
cancer. This will ensure that high risk patients are more thoroughly evaluated
using Saskatchewan's existing colonoscopy resources.

    A photo opportunity is available at Phenomenome's Saskatoon facility;
there will be opportunities for exterior and interior laboratory footage.
Please confirm attendance with:
    Christie Gradin
    306-244-8233, ext 212
    Location: 204-407 Downey Road, Saskatoon, SK
    Time: 1:30 pm, June 11, 2008

For further information:

For further information: Media Contact: Alix Hayden, Director, Business
Development, Phenomenome Discoveries Inc., Office: (306) 244-8233, ext 210,
Cell: (306) 261-5834,,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890